PubMed Health⌕ Search

Biomedical subjects

I Iwan-Zietek

Publications and source records attributed to I Iwan-Zietek.

At least 19 recordsLinked to original sources
PubMed1998

[Von Willebrand factor in plasma of patients with rheumatoid arthritis and lupus erythematosus].

The plasma levels of von Willebrand factor antigen (vWf:Ag) were evaluated for groups of 31 patients with rheumatoid arthritis and 34 patients with lupus erythematosus. The control group consisted of 34 healthy volunteers. In both groups the levels of vWf:Ag were increased to 243% and 240% respectively. The levels of vWf:Ag were also analysed statistically for the correlation with age of patients, time of the duration of disease and fibrinogen levels. No correlations were found. Obtained results suggest that measurements of vWf:Ag concentrations may be useful as potential marker of endothelial injury.

Adult↗
PubMed1997

[Antithrombin III activity in blood of patients with renal cancer].

The activity of antithrombin III (AT III) in the blood of 20 patients with renal carcinoma was examined. An increase of AT III activity in comparison with control group was observed. The increase of AT III activity in the blood of the patients with renal carcinoma can be as a result of compensatory mechanism safing these patients before thromboembolic complication. The measurement of AT III in renal carcinoma can be a prognostic symptom of haemorrhagic and thromboembolic complications.

Adult↗
PubMed1997

[The activity of protein C in the blood of patients with bladder carcinoma].

The activity of Protein C in the blood of patients with bladder carcinoma was examined. The average of Protein C activity was similar both in bladder carcinoma and in control group. The disperse of Protein C activity in bladder carcinoma was more greater than in control. In two patients with bladder carcinoma the bleeding with low activity of Protein C was observed. The low activity of Protein C in the blood of patients with bladder carcinoma can be the symptoms of an increased risk of thromboembolic complications.

Aged↗
PubMed1997

[The activity of alpha-2 macroglobulin in the blood of patients with prostatic carcinoma].

The activity of alpha 2-macroglobulin in the blood of the patients with prostatic carcinoma (PC) and benign prostatic hyperplasia (BPH) was examined. It was shown an decrease of alpha 2-macroglobulin in patients with prostatic carcinoma in comparison with control group consisted of the patients with benign prostatic hyperplasia. The low activity of alpha 2-macroglobulin in the blood od the patients with PC can be a symptom of an increase risk of haemorrhagic complications.

Aged↗
PubMed1997

[The influence of some surgical procedures on the activity of protein C].

Protein C is the important regulating factor of coagulation and fibrinolytic system. It is known that surgery causes disturbances of haemostasis. The aim of work was to study the influence of different kind of surgery on the protein C activity. The study contained 102 operated patients in whom vascular operation (20), operation of prostate because of carcinoma (20) and hypertrophy (40), cholecystectomy (12) and operation of hernia (10) were performed. Protein C activity was measured using Kabi Diagnostika test applying chromogenic substrate. In the most of patients surgery caused on the 0 and 1st postoperative day the decrease of protein C activity and the return to the preoperative values in the next few days. The exception was the hernia operation which did not diminish protein C activity. It seems that the decrease of protein C after surgery was the effect of consumption of it in the extremely activated coagulation and fibrinolytic system during operation.

Aged↗
PubMed1997

[Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia].

In the 20 patients with prostatic carcinoma (PC) and the 18 with benign prostatic hyperplasia (BPH) the level of tissue type plasminogen activator (t-PA:Ag) was examined. As a compared group consisted of 24 healthy volunteers. In the urine of examined patients with PC and BPH and control the t-PA:Ag was absent or present only in trace amounts. We concluded that the t-PA:Ag in the urine of patients with PC can not be as a marker in the diagnosis of prostatic diseases especially in the prostatic carcinoma.

Aged↗
PubMed1997

[Activity of antithrombin III in the blood of patients with bladder cancer].

The activity of antithrombin III (AT III) in the blood of patients with bladder carcinoma was examined. It was shown an increase of AT III activity in comparison with control group. The changes of AT III activity in the blood of patients with bladder carcinoma can be the symptoms of an increased risk of haemorrhagic or thromboembolic complications.

Aged↗
PubMed1997

[Tissue type plasminogen activator antigen in urine of patients with bladder cancer].

In urine of 25 patients with bladder carcinoma the antigen of tissue type plasminogen activator (t-PA) was assessed. The level of t-PA was much higher in patients with bladder carcinoma in comparison with a control group. We also analyzed the level of t-PA between patients with superficial and invasive bladder carcinoma the level of t-PA was higher. In conclusion, there is t-PA in urine of patients with bladder carcinoma and its level is correlated with staging of neoplasm.

Aged↗
PubMed1997

[Fibrinolysis process in blood of patients with bladder carcinoma].

In patients with bladder carcinoma a shorter ELT, and increased concentrations of EDP and t-PA were observed. These indicate on fibrinolysis activation caused by the released of t-PA. The increased fibrinolytic activity can be a cause of hemorrhagic complication occurring sometimes in bladder carcinoma. We observed much stronger activation of fibrinolysis in patients with an advanced bladder carcinoma.

Aged↗
PubMed1996

[Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia].

The pre- and postoperative activity was studied of antithrombin III (AT III) and alpha 2-antiplasmin (alpha 2-AP) in blood of 40 patients subjected to transurethral prostatic electroresection due to benign prostatic hyperplasia (BPH). For comparison of the obtained results a control group was formed from patients with other diseases of the genitourinary system with exception of neoplasms. The activity of AT III and alpha 2-AP before the operation was similar to that in the control group. Intraoperatively (day 0) and on the first day after the operation, a statistically significantly lower activity of AT III and alpha 2-AP was found in the patients with BPH in relation to the initial value as well as to the control group. On day 5 after the operation, normalization of AT III and alpha 2-AP activity was found. During operations of the prostate a release occurs of thromboplastins and plasminogen activators initiating the activation of blood clotting and fibrinolysis. The decrease of activity of AT III and alpha 2-AP could be caused by AT III and alpha 2-AP use-up in the process of inhibition of the created thrombin and plasmin.

Aged↗
PubMed1996

[Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].

The activity of alpha 1-antitrypsin in the blood of the patients with prostatic carcinoma and benign prostatic hyperplasia before and after the operation was examined. It was observed an increase of alpha 1-antitrypsin in the blood of patients with prostatic carcinoma and benign prostatic hyperplasia after the operation. In the blood patients of control group an increase of alpha 1-antitrypsin was observed too. The activity of alpha 1-antitrypsin in prostatic carcinoma was the highest during the whole observation period. The similar increase of the activity of alpha 1-antitrypsin after the operation in the blood of all groups of patients is connected with inflammatory reaction. The highest activity of alpha 1-antitrypsin in the blood of patients with prostatic carcinoma is the proof that the malignant neoplasm is associated with much more inflammatory reaction and the further hormonal treatment can be connected with a risk of thromboembolic complications.

Aged↗
PubMed1996

[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor].

In the blood of 20 patients with prostatic carcinoma the level of alpha 2-antiplasmin and plasminogen were examined. The control group consisted of 20 patients with benign prostatic hyperplasia. The low activity of alpha 2-antiplasmin in the blood of the patients with prostatic carcinoma was observed. The level of plasminogen was similar in both groups and it was in the low part of laboratory normal range. We concluded that the low levels of plasminogen and alpha 2-antiplasmin were a result of their consumption during activation of fibrinolysis process. The measurement of the alpha 2-antiplasmin and plasminogen can be useful to predict a risk of bleeding complications in the patients with prostatic carcinoma and benign prostatic hyperplasia.

Aged↗
PubMed1996

[Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor].

The activity of alpha 1-antitrypsin in patients with prostatic carcinoma and benign prostatic hyperplasia was examined. The activity of alpha 1-antitrypsin was higher in patients with prostatic carcinoma. The higher activity of alpha 1-antitrypsin is good prognostic sign for patients with prostatic carcinoma because it is born of large defense possibilities in these patients against the disease.

Aged↗
PubMed1996

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].

In 30 patients with prostatic carcinoma a higher of t-PA, a low of PAI-1, alpha 2-antiplasmin and plasminogen activity with increased fibrin degradation products (FDP) level and a short euglobulin lysis time (ELT) were observed. Following surgery a further increased of fibrinolytic activity occurred. The activity of t-PA and PAI-1 were higher than before operation. Apart from that we observed a decreased of plasminogen and alpha 2-AP with further increased level of FDP. On 5-th day the values of examined parameters were similar as before the operation.

Aged↗
PubMed1996

[Activity of protein C in blood of patients with prostatic carcinoma].

The activity of Protein C in the blood of the patients with prostatic carcinoma and benign prostatic hyperplasia was examined. It was observed a slightly decrease of activity of protein C in the blood the patients with prostatic carcinoma. The observation of the activity of Protein C is useful because it allow to differentiate from patients with prostatic carcinoma a group of high risk of haemorrhagic complications. The activity of Protein C may be a prognostic factor of a progress of a prostatic carcinoma.

Aged↗
PubMed1996

[Disseminated intravascular coagulation syndrome with secondary fibrinolysis activation in prostatic carcinoma].

We reported on a 74 year old patients with local advanced prostatic carcinoma. Following prostatic surgery an increased bleeding tendency was observed. The patients showed clinical and laboratory evidence for consumption coagulopathy with hyperfibrinolysis. The laboratory data were: marked decrease of AT III, Protein C, increase of thrombin/AT III complex level, fibrin degradation products (FDP) and antigen of t-PA. The treatment was ended successful.

Aged↗